UBS Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $37
Portfolio Pulse from Benzinga Newsdesk
UBS analyst David Dai has initiated coverage on Syndax Pharmaceuticals with a Buy rating and set a price target of $37.
October 24, 2024 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has initiated coverage on Syndax Pharmaceuticals with a Buy rating and a price target of $37, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target by a major financial institution like UBS is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100